微創醫療(00853.HK)為附屬引入投資者 持股降至約54%
微創醫療(00853.HK)訂立協議,旗下附屬上海默化人工智能科技同意向投資者出售目標公司微創(上海)醫療機器人之7.1429%註冊資本,代價為15億元人民幣(下同);目標公司的現有股東上海常隆同意向該等投資者轉讓目標公司2.3809%註冊資本,代價為5億元;該等投資者同意向目標公司注入額外資本15億元。
微創(上海)醫療機器人業務主要是專注於手術機器人研發與產業化。於交易完成後,上海默化於目標公司之持股將由64.756%減少至53.7722%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.